Publications

Publications

The academic group that founded TeloNostiX has published extensively in the fields of haematology and telomere biology.
Contact Us

“Browse TeloNostiX’s publications through the links below

Escudero, L., Cleal, K., Ashelford, K., Fegan, C., Pepper, C. Liddiard, K. and Baird, D.M. Telomere fusions associate with coding sequence and copy number alterations, driving genome complexity in CLL. Leukemia, doi: 10.1038/s41375-019-0423-y (2019). 

Norris, K., Hillmen, P., Rawstron, A., Hills, R., Baird, D.M., Fegan, C.D. and Pepper, C. Telomere length predicts for outcome to FCR chemotherapy in CLL. Leukemia, doi.org/10.1038/s41375-019-0389-9 (2019).

Ngo, G.H.P., Hyatt, S., Grimstead, J.W., Jones, R.E., Hendrickson, E.A., Pepper, C. and Baird, D.M. PARP inhibition prevents escape from a telomere-driven crisis and inhibits cell immortalisation. Oncotarget, 9:37549-37563 (2018).

Williams, J., Heppel, N.H., Britt-Compton, B., Grimstead, J.W., Jones, R.E., Tauro, S., Bowen, D.T., Knapper, S., Groves, M., Hills, R.K., Pepper, C., Baird, D.M. and Fegan, C. Telomere length is an independent prognostic marker in MDS and provides novel pathogenic insights in de novo AML. British Journal of Haematology, 178: 240-2498 (2017).

Hyatt, S., Jones, R.E., Heppel, N.H., Grimstead, J.W., Fegan, C., Jackson, G.H., Allan, J.M., Pratt, G., Pepper, C. and Baird, D.M. Telomere length is a critical determinant for survival in multiple myeloma. British Journal of Haematology, 178: 94-98 (2017).

Strefford, J.C., Kadalayil, L., Forster, J., Mjj, R.Z., Parker, A., Lin, T.T., Heppel, N., Norris, K., Gardiner, A., Davies, Z., Gonzalez de, C.D., Else, M., Steele, A.J., Parker, H., Stankovic, T., Pepper, C., Fegan, C., Baird, D., Collins, A., Catovsky, D., Oscier, D.G. Telomere length predicts progression and overall survival in chronic lymphocytic leukemia: data from the UK LRF CLL4 trial. Leukemia 29:2411-2414 (2015).

Simpson, K., Jones, R.E., Grimstead, J. W., Hills, R., Pepper, C. and Baird, D.M. Telomere fusion threshold identifies a poor prognostic subset of breast cancer patients. Molecular Oncology 9:1186-1193 (2015).

Pepper, C., Baird, D. and Fegan C. Telomere analysis to predict chronic lymphocytic leukemia outcome: a STELA test to change clinical practice? Expert reviews in Hematology doi:10.1586/17474086.2014.969705 (2014).

Lin, T.T., Norris, K., Heppel, N.H., Pratt, G., Allan, J.M., Allsup, D.J., Bailey, J., Cawkwell, L., Hills, R., Grimstead, J.W., Jones, R.E., Britt-Compton, B., Fegan, C., Baird, D.M. and Pepper, C. Telomere dysfunction accurately predicts clinical outcome in chronic lymphocytic leukaemia, even in patients with early stage disease. British Journal of Haematology. 167: 214-223 (2014).

Jones, C., Pepper, C. and Baird, D.M. Telomere dysfunction and its role in haematological cancer. British Journal of Haematology 156: 573-587 (2012).

Britt-Compton, B., Lin, T. T., Ahmed, G., Weston, V., Jones, R. E., Fegan, C., Oscier, D. G., Stankovic, T., Pepper, C. and Baird, D. M. Extreme telomere erosion in ATM mutated and 11q deleted CLL patients is independent of disease stage. Leukemia 26: 826-830 (2012).

Pepper, C and Baird, D.M. Shortened telomeres - a driving force behind leukaemia? Future Oncology 6:1681-1686 (2010).

Lin, T. T., Letsolo, B. T., Jones, R. E., Rowson, J., Pratt, G., Hewamana, S., Fegan, C., Pepper, C. and Baird, D. M. Telomere dysfunction and fusion during the progression of chronic lymphocytic leukaemia: evidence for a telomere crisis. Blood 116: 1899-1907 (2010).

Lin, T. T., Hewamana, S., Ward, R., Taylor, H., Payne, T., Pratt, G., Baird, D., Fegan, C. and Pepper, C. Highly purified CD38+ sub-populations show no evidence of preferential clonal evolution despite having increased proliferative activity when compared with CD38- sub-populations derived from the same CLL patient. British Journal of Haematology 142: 595-605 (2008).

Have a question about our research?

Contact Us
Share by: